People · Operator
Named in public records as an officer, director or promoter · active 2023–2023 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Garuda Therapeutics, Inc. | — | Biotechnology | Series C | $158.0M | $380.2M | 2023 |
Laurence I Reid at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Laurence I Reid on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Carl Gordon | 1 | 24 |
| Raymond Kelleher | 1 | 4 |
| Steve Liapis | 1 | 3 |
| Eric Aguiar | 1 | 3 |
| Shaan I Gandhi | 1 | 2 |
| David Kirske | 1 | 2 |
| Adam Craig | 1 | 2 |
| Rahul Singhvi | 1 | 1 |
| Daniel I Janse | 1 | 1 |
| Eric I Aguiar | 1 | 1 |
| Carl I Gordon | 1 | 1 |
| Dhvanit I Shah | 1 | 1 |
| Raymond I Kelleher | 1 | 1 |
| Rahul I Singhvi | 1 | 1 |
| Geoff Meyerson | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.